Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) Research & Development (2021 - 2025)

Medicinova (MNOV) has disclosed Research & Development for 8 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development changed N/A to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $7.2 million for FY2025, 0.55% down from the prior year.
  • Research & Development for Q4 2025 was $1.9 million at Medicinova, up from $1.6 million in the prior quarter.
  • The five-year high for Research & Development was $2.6 million in Q2 2022, with the low at $794706.0 in Q3 2023.
  • Average Research & Development over 5 years is $1.9 million, with a median of $1.8 million recorded in 2024.
  • The sharpest move saw Research & Development crashed 67.62% in 2023, then soared 133.97% in 2024.
  • Over 5 years, Research & Development stood at $1.8 million in 2021, then skyrocketed by 38.11% to $2.5 million in 2022, then tumbled by 32.74% to $1.7 million in 2023, then rose by 12.64% to $1.9 million in 2024, then increased by 0.44% to $1.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.9 million, $1.6 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.